Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EPRX Stock Forecast 2026-2027
$7.08
Current Price
$435.44M
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to EPRX Price Targets
+168.4%
To High Target of $19.00
+97.7%
To Median Target of $14.00
+55.4%
To Low Target of $11.00
EPRX Price Momentum
-1.3%
1 Week Change
-11.7%
1 Month Change
+133.7%
1 Year Change
-6.2%
Year-to-Date Change
-24.0%
From 52W High of $9.32
+144.1%
From 52W Low of $2.90
📊 TOP ANALYST CALLS
Did EPRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Eupraxia is one of their latest high-conviction picks.
Latest EPRX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, EPRX has a bullish consensus with a median price target of $14.00 (ranging from $11.00 to $19.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $7.08, the median forecast implies a 97.7% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Kristen Kluska at Cantor Fitzgerald, projecting a 168.4% upside. Conversely, the most conservative target is provided by Brandon Folkes at HC Wainwright & Co., suggesting a 55.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EPRX Analyst Ratings
9
Buy
0
Hold
0
Sell
EPRX Price Target Range
Low
$11.00
Average
$14.00
High
$19.00
Current: $7.08
Latest EPRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EPRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 23, 2026 | William Blair | Lachlan Brown | Outperform | Initiates | $N/A |
| Mar 17, 2026 | HC Wainwright & Co. | Brandon Folkes | Buy | Maintains | $11.00 |
| Jan 15, 2026 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $19.00 |
| Jan 9, 2026 | HC Wainwright & Co. | Brandon Folkes | Buy | Reiterates | $12.00 |
| Aug 20, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Reiterates | $12.00 |
| Jul 24, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Initiates | $11.00 |
| Jun 26, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Initiates | $12.00 |
| Nov 14, 2024 | Rodman & Renshaw | Brandon Folkes | Buy | Initiates | $9.00 |
Eupraxia Pharmaceuticals Inc. (EPRX) Competitors
The following stocks are similar to Eupraxia based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Eupraxia Pharmaceuticals Inc. (EPRX) Financial Data
Eupraxia Pharmaceuticals Inc. has a market capitalization of $435.44M with a P/E ratio of -6.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -68.8%.
Valuation Metrics
Market Cap
$435.44M
Enterprise Value
$370.88M
P/E Ratio
-6.9x
PEG Ratio
-10.7x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+18.5%
Current Ratio
15.1x
Debt/Equity
0.2x
ROE
-68.8%
ROA
-39.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Eupraxia Pharmaceuticals Inc. (EPRX) Business Model
About Eupraxia Pharmaceuticals Inc.
What They Do
Develops innovative drug delivery technologies.
Business Model
Eupraxia Pharmaceuticals focuses on developing long-lasting medications for pain management and chronic diseases, generating revenue through the commercialization of its drug delivery products, such as EP-104IAR for osteoarthritis treatment.
Additional Information
Based in Victoria, Canada, the company is committed to addressing unmet medical needs and enhancing patient outcomes through advanced research in drug delivery systems, positioning itself as a significant contributor to the biotech industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
49
CEO
Dr. James A. Helliwell FRCPC, M.D.
Country
Canada
IPO Year
2024
Website
www.eupraxiapharma.comEupraxia Pharmaceuticals Inc. (EPRX) Latest News & Analysis
Latest News
New Strong Sell Stocks for April 2nd
8 days ago
Quick Summary
ACCO, CDE, and EPRX have been added to the Zacks Rank #5 (Strong Sell) List as of April 2, 2026.
Why It Matters
ACCO, CDE, and EPRX being ranked as Strong Sell indicates potential declines in stock performance, suggesting investors may need to reassess their positions in these companies.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
William Blair has begun coverage of Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), a biotech firm specializing in locally delivered, extended-release products in clinical development.
Why It Matters
William Blair's coverage initiation on Eupraxia Pharmaceuticals signals potential growth and investment interest in the company's innovative drug delivery technologies, impacting EPRX's stock outlook.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Eupraxia Pharmaceuticals (NASDAQ:EPRX, TSX:EPRX) reported its Q4 2025 financial results, focusing on its Diffusphere™ technology for drug delivery. All figures are in U.S. dollars.
Why It Matters
Eupraxia's financial results reveal its performance and potential, impacting investor confidence and stock valuation, particularly in the biotech sector focused on innovative drug delivery solutions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Eupraxia Pharmaceuticals priced a public offering of 6.43 million common shares at $7.00 each and pre-funded warrants at $6.99999, aiming for gross proceeds of ~$55 million.
Why It Matters
Eupraxia's public offering raises $55 million, enhancing its financial position. Successful funding can drive further development of its Diffusphere™ technology, impacting future growth and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Eupraxia Pharmaceuticals closed a public offering of 7.6M common shares at $7.00 each, raising approximately $63.2M to expand its pipeline and develop EP-104GI for eosinophilic esophagitis.
Why It Matters
Eupraxia Pharmaceuticals raised $63.2 million, enhancing its financial position and enabling advancement in drug development, which could lead to increased market valuation and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Eupraxia Pharmaceuticals has filed a preliminary prospectus for a public offering of common shares, following its base prospectus from February 2024. This includes a registration with the SEC.
Why It Matters
Eupraxia Pharmaceuticals' public offering can dilute existing shares, impacting stock price. Investors need to assess potential funding benefits against the risk of dilution.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About EPRX Stock
What is Eupraxia Pharmaceuticals Inc.'s (EPRX) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Eupraxia Pharmaceuticals Inc. (EPRX) has a median price target of $14.00. The highest price target is $19.00 and the lowest is $11.00.
Is EPRX stock a good investment in 2026?
According to current analyst ratings, EPRX has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.08. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EPRX stock?
Wall Street analysts predict EPRX stock could reach $14.00 in the next 12 months. This represents a 97.7% increase from the current price of $7.08. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Eupraxia Pharmaceuticals Inc.'s business model?
Eupraxia Pharmaceuticals focuses on developing long-lasting medications for pain management and chronic diseases, generating revenue through the commercialization of its drug delivery products, such as EP-104IAR for osteoarthritis treatment.
What is the highest forecasted price for EPRX Eupraxia Pharmaceuticals Inc.?
The highest price target for EPRX is $19.00 from Kristen Kluska at Cantor Fitzgerald, which represents a 168.4% increase from the current price of $7.08.
What is the lowest forecasted price for EPRX Eupraxia Pharmaceuticals Inc.?
The lowest price target for EPRX is $11.00 from Brandon Folkes at HC Wainwright & Co., which represents a 55.4% increase from the current price of $7.08.
What is the overall EPRX consensus from analysts for Eupraxia Pharmaceuticals Inc.?
The overall analyst consensus for EPRX is bullish. Out of 3 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $14.00.
How accurate are EPRX stock price projections?
Stock price projections, including those for Eupraxia Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 10, 2026 7:11 AM UTC